











## Case study: bladder cancer

### The challenge

-  Bladder cancer is the fifth most common cancer in the Western world
-  More than 600,000 people worldwide are diagnosed with the disease each year – including 10,000 in the UK
-  Bladder cancer accounts for 250,000 deaths annually worldwide, with 5,555 deaths in the UK
-  49% of cases of the disease are preventable
-  If diagnosed early, more than 90% of patients will survive for five years or more, compared to just 36% of those with a late diagnosis

### Our impact

-  Our researchers have developed a new urine test which reduces the need for invasive and time-consuming cystoscopy procedures when diagnosing bladder cancer
-  The test – GALEAS® Bladder – is based on a biomarker panel of 443 genetic mutations that are common in bladder cancer, and uses a highly sensitive liquid biopsy technology developed by industry partner Nonacus
-  In a study of 165 people with confirmed bladder cancer, the test was successful in detecting the disease in 144 of them (87%)
-  The test can also detect recurrent disease before it is visible via cystoscopy
-  30,000 cystoscopies are performed each year in England with 80% of patients found to have no cancer or abnormalities – the new test has the potential to reduce the costs associated with this procedure as well as being more comfortable and less stressful for patients